Company profile
Zevra Therapeutics, Inc.
NASDAQ: ZVRA · Healthcare · Biotechnology
#344 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
70BFH 84DQ 51GM 71SS 62
v0.1 · 65/100 weight · provisional
↑ net margin, return on equity · ↓ growth stability, filing timeliness
Methodology →Revenue TTM
$122.3M
Rev growth YoY (TTM)
+201.3%
Net income (FY)
$83.2M
Employees
61
as of 2026-08-11
Market cap
$678.6M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$106.5M$106.5M2025
Net income$83.2M$83.2M2025
Operating income-$62.9M-$62.9M2025
Total assets$284.7M$284.7M2025
Liabilities$130.1M$130.1M2025
Equity$154.7M$154.7M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2023
By product
License100%
By geography
Not disclosed.
The read
What is Zevra Therapeutics, Inc.’s revenue?
Zevra Therapeutics, Inc. booked $106.5M in FY2025 revenue, growing 351% year over year — faster than 92% of Healthcare companies we track, at a 78.2% net margin.
Peers · Healthcare
Century Therapeutics, Inc.48DAuxly Cannabis Group Inc.76B+Theravance Biopharma Inc75B+Zymeworks Inc.55COwlet, Inc.49DPlanet 13 Holdings Inc.44DNeighbors
Osceola →Key facts
CEONeil F. McFarlane
SectorHealthcare
IndustryBiotechnology
HeadquartersCelebration, FL
ExchangeNASDAQ: ZVRA
Employees61
IPO date2015-04-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.